24
Participants
Start Date
July 8, 2022
Primary Completion Date
March 19, 2024
Study Completion Date
March 19, 2024
Marcaine® 100mg/20mL (0.5%) bupivacaine solution for Injection
"Subjects in this arm will receive a single administration of Marcaine® at the 150 mg.~Marcaine® will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
ND-340 (Bupivacaine Microsphere), 300 mg/vial bupivacaine for extended-release injectable suspension
"Subjects in this arm will receive a single administration of ND-340 at the specified dose (90-320 mg).~ND-340 will be administered under ultrasound guidance with a total volume of 40 mL, of which 20 mL will be used via adductor canal block (ACB) and the other 20 mL will be used as IPACK block (interspace between the popliteal artery and the capsule of the posterior knee)."
National Taiwan University Hospital, Taipei
Lead Sponsor
Nang Kuang Pharmaceutical Co., Ltd.
INDUSTRY